Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SLGL Sol-Gel Technologies Ltd. daily Stock Chart
SLGL [NASD]
Sol-Gel Technologies Ltd.
Healthcare | Biotechnology | Israel
financial highlights | statements
Index- P/E- EPS (ttm)-1.45 Insider Own71.84% Shs Outstand18.42M Perf Week2.92%
Market Cap123.23M Forward P/E- EPS next Y-2.07 Insider Trans- Shs Float5.34M Perf Month16.15%
Income-25.80M PEG- EPS next Q-0.61 Inst Own25.70% Short Float0.93% Perf Quarter-6.17%
Sales0.30M P/S410.77 EPS this Y-52.00% Inst Trans0.08% Short Ratio3.47 Perf Half Y5.35%
Book/sh4.28 P/B1.56 EPS next Y-16.30% ROA-37.90% Target Price19.40 Perf Year-43.26%
Cash/sh0.78 P/C8.62 EPS next 5Y- ROE-54.00% 52W Range5.41 - 12.31 Perf YTD11.13%
Dividend- P/FCF- EPS past 5Y- ROI60.00% 52W High-45.65% Beta-
Dividend %- Quick Ratio16.00 Sales past 5Y- Gross Margin- 52W Low23.66% ATR0.27
Employees49 Current Ratio16.00 Sales Q/Q- Oper. Margin- RSI (14)69.50 Volatility4.43% 3.95%
OptionableNo Debt/Eq0.00 EPS Q/Q48.40% Profit Margin- Rel Volume0.18 Prev Close6.50
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 BMO Payout- Avg Volume14.31K Price6.69
Recom- SMA209.46% SMA5010.00% SMA200-5.50% Volume2,608 Change2.92%
Feb-06-19 12:27PM  What Percentage Of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares Do Insiders Own? Simply Wall St. +6.55%
09:23AM  Sol-Gel Technologies Announces FDA Approval for Perrigos Generic Acyclovir Cream, 5% GlobeNewswire
08:45AM  Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5% PR Newswire
Jan-15-19 07:05AM  Sol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization GlobeNewswire
Dec-20-18 09:42AM  Who Has Been Buying Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares? Simply Wall St.
Dec-17-18 07:05AM  Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris GlobeNewswire +5.35%
Dec-04-18 04:05PM  Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo GlobeNewswire
Nov-29-18 04:05PM  Sol-Gel Technologies Announces Participation in Upcoming Investor Conference GlobeNewswire
Nov-21-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within MongoDB, DLH, Sol-Gel Technologies, National Vision, NCS Multistage, and NI New Research Emphasizes Economic Growth GlobeNewswire
Nov-13-18 04:05PM  Sol-Gel Technologies Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 04:05PM  Sol-Gel Technologies Announces Participation in Upcoming Investor Conference GlobeNewswire
Nov-01-18 04:05PM  Sol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo GlobeNewswire
Sep-25-18 04:05PM  Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea GlobeNewswire -6.21%
Sep-19-18 07:55AM  How Financially Strong Is Sol-Gel Technologies Ltd (NASDAQ:SLGL)? Simply Wall St.
Sep-13-18 04:05PM  Sol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors GlobeNewswire
Sep-04-18 04:05PM  Sol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris GlobeNewswire
Aug-15-18 04:05PM  Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo GlobeNewswire
Aug-08-18 07:05AM  Sol-Gel Technologies Reports Second Quarter 2018 Financial Results GlobeNewswire
Jun-18-18 04:33PM  Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea GlobeNewswire -6.14%
May-29-18 04:05PM  Sol-Gel Technologies Announces Participation in Upcoming Investor Conferences GlobeNewswire
May-15-18 04:05PM  Sol-Gel Technologies Reports First Quarter 2018 Financial Results GlobeNewswire +12.40%
May-01-18 09:14PM  How Do Analysts See Sol-Gel Technologies Ltd (NASDAQ:SLGL) Performing Over The Next Few Years? Simply Wall St.
Mar-26-18 04:05PM  Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website GlobeNewswire +5.24%
07:05AM  Sol-Gel Technologies Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-15-18 04:30PM  Sol-Gels Phase 2 Data on TWIN and VERED to be Presented at the 2018 American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-05-18 04:01PM  Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -12.97%
Jan-31-18 06:46PM  Sol-Gel Technologies Ltd. Announces Pricing of Initial Public Offering GlobeNewswire
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
open in yahoo | open in reuters | open in google